Hepatitis B affects approximately 350 million people worldwide, and an estimated 1.25 million people in the United States. Although most people infected with the virus do not develop significant hepatic disease from hepatitis B, 15-40% will develop serious complications. These complications include cirrhosis, the development of hepatocellular carcinoma , and hepatic decompensation. Patients with renal failure have increased risk of acquiring the virus through blood transfusions and contact with bodily fluids at hemodialysis centers, and of developing complications from hepatitis B virus infection. Renal transplant patients are at increased risk for exacerbations of hepatitis B with immunosuppression. Thus, it is crucial for the nephrologist to have a clear understanding of the natural history and treatment of hepatitis B, both pre-and post-renal transplant. 
Hepatitis B affects approximately 350 million people worldwide, and an estimated 1.25 million people in the United States. Although most people infected with the virus do not develop significant hepatic disease from hepatitis B, 15-40% will develop serious complications. These complications include cirrhosis, the development of hepatocellular carcinoma (HCC), and hepatic decompensation. Patients with renal failure have increased risk of acquiring the virus through blood transfusions and contact with bodily fluids at hemodialysis (HD) centers, and of developing complications from hepatitis B virus (HBV) infection. Renal transplant patients are at increased risk for exacerbations of hepatitis B with immunosuppression. Furthermore, patients with chronic hepatitis B may develop renal disease secondary to HBV infection. Thus, it is crucial for the nephrologist to have a clear understanding of the natural history and treatment of hepatitis B, both pre-and post-renal transplant.
VIROLOGY
Hepatitis B is a hepadnavirus -a double stranded DNA virus. Its life cycle begins with infection of the hepatocyte. Once inside the nucleus of the hepatocyte, the HBV DNA polymerase starts repairing the gap in the positive strand to form a covalently closed circular DNA (cccDNA), which is the form in which HBV persists in host cells and serves as the template for the pregenomic RNA. The viral mRNA by host RNA polymerase is then translated in the cytoplasm to produce HBV surface, core, polymerase, and X proteins. In the cytoplasm, viral capsids are assembled, incorporating genomic viral RNA with a molecule of HBV DNA polymerase. The HBV DNA polymerase has a reverse transcriptase function that catalyzes the synthesis of the negative strand of DNA, which, in turn serves, as the template for the positive strand synthesis. These nucleocapsids can go back to the nucleus and be recycled as additional cccDNA molecules but the majority of them are transported via the endoplasmic reticulum to form mature virions that are subsequently released into the pericellular space.
1,2 Thus, cccDNA is maintained both by new virions penetrating the cell and being converted by host cell mechanisms to cccDNA and by intracellular viral genomes being transported back to the nucleus. Most anti-viral therapies do not target cccDNA, which partly explains why HBV DNA levels rapidly rise once treatment is stopped.
HBV IN THE RENAL PATIENT
Both the prevalence and incidence of HBV among patients with end-stage renal disease has declined in the United States and in Europe. This is largely the result of the introduction of universal precautions, screening of the blood supply, the use of erythropoietin and its analogs with resultant decreased transfusion requirements, and the practice of segregating hepatitis B surface antigen (HBsAg) ( þ ) patients from those who are HBsAg (À). The CDC estimates that the prevalence of HBsAg ( þ ) patients among HD patients has declined from 7.8 to 0.9%, with an estimated incidence of disease in 2000 of 0.05%. 3 Despite these efforts, viral transmission has been reduced but not eliminated in HD patients. Transmission likely occurs through contamination of multi-dose vials and other occult parenteral exposures. All patients on HD should be screened for HBV and vaccinated if not immune. The optimal screening regimen, however, is unclear. In most centers, this is done by testing for HBsAg. However, a recently published population-based study suggests that hepatitis B is 4-5 times more prevalent in a North American HD population than is suggested by relying on standard HBsAg testing. 4 Patients who are negative for HBsAg and who have HBV DNA have occult HBV. Occult HBV is a poorly defined clinical entity but traditionally describes patients who have HBV DNA but are HBsAg (À). It includes patients who are HBcAb ( þ ), known as seropositive, and those who are HBcAb (À), known as seronegative. As untreated hepatitis B has serious implications, these authors propose that all HD patients be screened with hepatitis B DNA testing. It should be emphasized, though, that this finding has yet to be confirmed and that testing all patients on HD for HBV DNA would be very costly. A more cost-effective strategy might be testing those patients who test positive for HBcAb, as it is established that occult HBV is much more common among HbcAb ( þ ) patients, compared to HbcAb (À) patients 5, 6 At the current time, there is no conclusive data to recommend further screening in HBsAg (À) patients.
Hepatitis B is associated with high mortality rates among renal patients. Although hepatitis C has been the biggest concern among renal patients owing to the large numbers of people affected, hepatitis B is associated with a higher mortality risk. In a study of 286 renal transplant patients, liver-related death was the most common cause of death in HBV-positive patients, whereas HCV-positive patients were more likely to die of a cardiovascular event. 7 Additionally, HBsAg seropositivity was found to be an independent and significant risk factor for graft failure following kidney transplantation. 8 In addition to patients with renal disease and hepatitis B infection, there are patients with hepatitis B who have renal disease as a result of the HBV virus itself. Hepatitis B-induced renal disease encompasses a variety of clinical entities that manifest with varying degrees of severity. Most of these conditions are mediated by the deposition of immune complexes, although a variety of pathologic mechanisms have been described. 9 In the pediatric population, HBVassociated nephropathy is typically asymptomatic and detected on routine screening. In adults, the most common manifestations are proteinuria and the nephrotic syndrome. It is not clear which patients with HBV are more likely to develop renal disease. The natural history of HBV-induced renal disease is also not very well established. It is known that some cases resolve spontaneously, and that some cases of remission are associated with HBeAg seroconversion. Steroids do not seem to be of benefit in HBV-induced renal disease. 10 
PATIENT POPULATIONS
Chronic hepatitis B is defined by the presence of HBsAg for more than 6 months with histologic changes on liver biopsy or persistently elevated alanine aminotransferase (ALT). We divide HBV patients into two groups, e antigen (HBeAg) positive and those that are e antigen negative (usually with antibody to e antigen, HBeAb). Patients who are HBeAg positive have active replication with wild-type virus, with high levels of circulating HBV DNA. Those who are HBeAg negative can further be classified into the actively replicating 'pre-core' mutants, and those who are quiescent, previously known as the 'healthy or inactive carrier'. Pre-core mutant HBV has a mutation in the pre-core region or the basic core promoter region of the HBV DNA genome that allows replication without e antigen production. These patients tend to have fluctuating levels of HBV DNA in their blood and are more common in Southern Europe, the Middle East, and Asia, whereas the e antigen-positive patients are typically found in North America and Northern Europe. HBe antigennegative patients with pre-core mutations tend to have a worse prognosis and poorer response to therapy than e antigen-positive patients.
The term 'inactive or healthy carrier state' is a misnomer. Although patients with HBsAg in their blood and normal ALT tend to have little evidence of inflammation on liver biopsy, low levels of DNA in the serum, and a better prognosis, they do have both circulating DNA and cccDNA and, therefore, are not 'inactive' . These patients can have progressive liver disease and/or HCC. However, currently there is no evidence to support treatment with anti-viral therapy owing to low-level replication that cannot be suppressed with current therapy.
THERAPY FOR HEPATITIS B
There are currently five medications approved for the treatment of hepatitis B -interferon alfa-2b, pegylated interferon alfa 2a, lamivudine, adefovir, and entecavir. The arsenal of therapeutic options, diverse patient population, and lack of clear guidelines makes the treatment of hepatitis B a daunting task.
Goals of therapy
The goals of therapy in HBV depend on the degree of liver injury and state of replication. Suppression of viral replication and prevention of the development of fibrosis are the primary goals for any patient. Seroconversion from HBsAg positivity to HBsAb positivity is the rarely achieved, but optimal goal of therapy. It is unclear whether this represents complete and permanent viral clearance or cure, however. For those patients with wild-type virus (HBeAg positive), an important end point is seroconversion to HBeAb positivity, which tends to lead to a durable response with low levels of HBV DNA and normal ALT levels. For pre-core mutants who do not produce HBeAg, HBV DNA levels need to be followed to assess response to therapy.
THERAPEUTIC AGENTS Interferons
Interferon has the longest track record in HBV treatment and has immunomodulatory, anti-fibrotic, and anti-viral effects. However, interferon is parenterally administered and has significant side effects including an influenza-like syndrome, myelosuppression, fatigue, and depression. Pegylated interferon, created by attaching a polyethylene glycol multimer to interferon, improves the pharmacokinetics of the drug, and allows for a weekly dosing schedule and reliable drug levels. Pegylated interferon is associated with a 30-35% HBeAg seroconversion rate, compared to 16-20% with standard interferon.
In two recently published, multi-center, randomized controlled trials in both HBeAg-positive and -negative patients, pegylated interferon was shown to be more effective than lamivudine alone at reducing HBV DNA as well as inducing HBsAg and HBeAg seroconversion. In both studies, the combination of pegylated interferon with lamivudine was more effective than lamivudine alone but not better than pegylated interferon monotherapy. 11, 12 The increased convenience and efficacy of pegylated interferon has virtually eliminated the use of standard interferon in HBV. Of note, patients with renal disease (broadly defined as creatinine values 1.5 times the upper limit of normal or greater than 1.5 mg per deciliter) were excluded from these studies and there is very limited data supporting the use of interferon therapy in patients with renal disease. Furthermore, interferon is not used in the post-transplant setting owing to its association with acute rejection. 13 Interferon may have a role in the treatment of hepatitis B-induced membranous nephropathy. Three months of interferon therapy has been shown to be effective in eliminating proteinuria in a small number of patients. 14 
Lamivudine
Lamivudine is a cytosine analog that inhibits HBV reverse transcriptase. Lamivudine has been widely used in HBV, particularly for renal patients, given its efficacy and tolerability. It can also be used effectively in patients who have been treated with interferon previously. It is administered once daily, typically at a dose of 100 mg, and is generally well tolerated and safe in long-term studies. Side effects, when they occur, are generally mild and include headache, nausea, and vomiting. Dosage is reduced in patients with some degree of renal insufficiency according to their creatinine clearance (see Table 1 ). Lamivudine has been shown to induce both seroconversion and a histological response in addition to reducing HBV DNA. Data on lamivudine use in patients with renal disease is limited to uncontrolled studies on small numbers of patients. However, several studies have shown lamivudine to be effective at both reducing HBV DNA levels and normalizing ALT in patients post-renal transplant. 15, 16 However, when used in the post-renal transplant setting, lamivudine response rates have been somewhat lower than those seen in patients without renal disease -with up to a 45% rate of non-response or relapse after 36 months of therapy. 17 Unfortunately, duration of oral anti-viral therapy is related to both the likelihood of response and to the development of resistance. Although HBeAg seroconversion rates of 21, 29, and 40% at 1, 2, and 3 years, respectively 18 are encouraging, these results are tempered by resistance rates, which are 14-20% at 1 year and 69% at 5 years. 19 Furthermore, use of lamivudine in HBeAg-negative patients is associated with more rapid resistance -60% at 4 years. 20 There is also data from liver transplant patients that suggest that resistance develops more quickly in the post-transplant setting. 21 The role of lamivudine is evolving for patients with HBVinduced renal disease. In a recent study, HBsAg ( þ ) patients with membranous nephropathy treated with lamivudine therapy for 1 year had reduced proteinuria and decreased HBV DNA compared to historic control patients taken from the pre-lamivudine era. 22 Current recommendations generally are to treat HBV-induced renal disease with indefinite oral anti-viral therapy aimed at sustained suppression of viral replication. This may, however, require combination therapy to prevent development of viral resistance. Lamivudine resistance is a major clinical problem caused by a mutation in the YMDD locus of the HBV DNA polymerase. In a study of 29 patients with rising HBV DNA post-renal transplant, lamivudine therapy was associated with detectable resistance in 48.3% of patients during a mean follow-up period of 68.7 months, all of whom showed YMDD mutations. Resistance was not related to patient demographics, HBeAg status, seroconversion rates, or genotype. Of these patients, 78.6% who developed the YMDD mutation had a flare of their hepatitis, characterized by an increase in ALT, but this was transient in 36% and chronic in 54.5%. One patient suffered an episode of hepatic decompensation, but all survived. 23 Lamivudine has also been studied in patients pre-renal transplant. Lamivudine was given to three different patient populations: those who were HBV DNA-positive pre-renal transplant, those who were HBV DNA-negative post-renal transplant, and patients post-renal transplant with evidence of hepatitis. It was shown that lamivudine use before transplant was associated with lower rates of reactivation of hepatitis B than its use post-transplant in response to evidence of hepatitis. 24 Survival post-transplant was improved in patients who were treated with lamivudine pretransplant in a preemptive strategy. 25 This data highlights a lower threshold for treatment of HBV before kidney transplantation to improve post-transplant outcomes.
In our practice, the high rate of resistance coupled with the availability of other therapeutic options limits the use of lamivudine to a few clinical scenarios, specifically, acute liver failure owing to hepatitis B, pregnancy, prophylaxis against the reactivation of hepatitis B in the setting of immunosuppression, most commonly chemotherapy, and pre-and/or post-renal transplant for patients with low or negative viral loads pre-transplant. More frequently, lamivudine is used in conjunction with other anti-virals such as adefovir as resistance is so common. The prevalence of lamivudine resistance underscores the need for other therapies and the further study of combination therapy.
Adefovir
Adefovir dipivoxil is a phosphonate nucleotide analog of adenosine, which competitively binds HBV DNA polymerase and serves as a chain terminator. Adefovir is used at a dose of 10 mg daily and its utility has been shown in naive HBeAg positive and negative patients, lamivudine-resistant patients, patients co-infected with HIV, and in the post-liver transplant setting. 26, 27 In studies of patients who are naive to HBV therapy, adefovir has been shown to reduce HBV DNA levels to undetectable levels and normalize ALT in 21 and 48% of patients studied, respectively. Forty-eight weeks of adefovir was associated with a 12% HBeAg seroconversion rate. 28 More importantly, two recent studies have looked at the use of adefovir in lamivudine-resistant HBV in both compensated and decompensated liver disease. Patients with the YMDD mutation were randomized to lamivudine plus placebo or 10 mg of adefovir for 52 weeks. Patients with compensated HBV experienced a significant decline in HBV DNA levels and normalized ALT, (85 and 31%) respectively, with adefovir compared to 11 and 6% of those patients given lamivudine plus placebo. In decompensated patients, the use of adefovir not only resulted in a statistically significant difference in HBV DNA levels and ALT levels, but, more importantly, an overall clinical improvement as measured by the Child Turcotte Pugh (CTP) score. 29 Other studies have confirmed these results and shown similar effect of lamivudine plus adefovir to adefovir alone, raising the suggestion that the continuation of lamivudine might not add any benefit. 30 However, it is likely that adefovir resistance can be delayed or eliminated when lamivudine is used in combination with adefovir owing to a lack of any crossresistance between the two drugs. Although patients with significant renal disease were excluded from these studies, significant increases in creatinine were not seen on adefovir therapy.
Unfortunately, though adefovir is also effective at inhibiting HBV viral replication in HBeAg-negative patients, the effect is transient and viral rebound occurs when treatment is stopped. In one study, patients received adefovir for 144 weeks with excellent viral inhibition, low rates of resistance, and minimal side effects but near universal relapse when the drug was stopped after only 48 weeks of therapy. 31 These results underscore the fact that optimal duration of therapy in HBeAg-negative patients is not known. Resistance to adefovir has been reported in 5.9% of HBeAg (À) patients after 144 weeks of therapy when used as monotherapy. 32 The use of adefovir in patients with renal disease has been limited by concern for potential renal side effects. In animal studies, renal toxicity, characterized by a tubular nephropathy and elevated creatinine, is the dose-limiting side effect. These changes developed, however, at doses 3-8 times greater than the recommended dose for humans, which is 10 mg daily, and at higher doses (X30 mg/day) in HIV and HBV þ patients. At the dose of 10 mg, however, significant renal side effects have not been seen. So, though patients should have their renal function monitored while on adefovir, it has been shown to be safe to use in renal patients. 33 Additionally, adefovir has been studied in patients with lamivudineresistant HBV and renal disease, and has been shown to be both safe and efficacious in this population. 34 Adefovir dosing needs to be dose adjusted in patients on HD (See Table 1 ).
Entecavir
Entecavir is a guanosine analog that inhibits HBV DNA polymerase at both the priming and elongating steps (of both positive and negative strands) of DNA synthesis. It is 30 times more potent than lamivudine in suppressing viral replication.
In multi-center, double-blind randomized trials comparing entecavir to lamivudine in both HBeAg positive and negative patients, entecavir was shown to result in larger reductions in HBV DNA than lamivudine. At a dose of 0.5 mg daily, 83% of patients treated with entecavir had undetectable DNA compared to 58% of those treated with lamivudine. 35 In recently published data of HBeAg ( þ ) patients, 72% of those on 0.5 mg of entecavir experienced histologic improvement, compared to 62% of those on lamivudine (P ¼ 0.0085) and 69% had undetectable HBV DNA levels, compared to 38% in the lamivudine group (Po0.0001). HBeAg seroconversion rates, however, of 21% with entecavir and 18% with lamivudine were not significantly different. 36 In HBeAg (À) patients, 70% had histologic improvement and 91% had undetectable HBV DNA patients in the entecavir group compared to 61% (P ¼ 0.0143) and 73% (Po0.0001), respectively, of those on lamivudine. 37 Entecavir at a higher dose of 1 mg/day has been studied in lamivudine-resistant patients with 55% of the entecavir group experiencing histologic improvement compared to 28% of the group that continued on lamivudine (Po0.0001). Resistance to entecavir is very low, but was seen in over 7% of the lamivudine-resistant patients treated with entecavir for 1 year, making it unlikely to be the drug of choice as a monotherapy in this situation. A randomized trial of entecavir and adefovir is currently underway in patients with decompensated liver disease.
The potential advantage to entecavir is its safety profile, particularly in renal patients. Although the dose of entecavir needs to be adjusted for patients with renal disease (see Table 1 ), there is no known renal toxicity of the drug itself. Long-term resistance remains undefined with entecavir, and it needs to be taken on an empty stomach, separated from food and other drugs by 2 h.
DRUGS IN DEVELOPMENT
Tenofovir, a cousin of adefovir, has anti-HBV activity, is currently FDA-approved for HIV, and is in Phase III trials for HBeAg-positive and HBeAg-negative HBV. Tenofovir has been studied in several small, non-randomized studies. It is often used in HIV/HBV co-infected patients, but has been used in mono-HBV-infected patients as well. Emtricitabine (FTC) is a cytosine nucleoside analog that is also active against HBV and is entering phase II and III trials including combination trials with tenofovir. In a study of 30 HBeAg ( þ ) patients, 48 weeks of adefovir plus emtricitabine was associated with a median decrease of 3.48log 10 copies/ml compared to a median drop of 2.22log 10 copies/ml in the group on adefovir monotherapy (Po0.01). 38 Given its structural similarity to lamivudine, there is concern about cross-resistance in patients with YMDD mutant virus.
Telbivudine (Ldt) is another nucleoside with specific activity against HBV. In early studies, this drug has been shown to have an excellent safety profile and to be efficacious at reducing HBV DNA levels and is also in Phase III studies.
TREATMENT ALGORITHMS
Our approach to classifying HBV patients is outlined in Figure 1 . All patients with HBsAg should have HBV DNA levels, HBeAg, HBeAb, and alpha-fetoprotein checked. Additionally, all patients should have hepatic imaging at regular intervals (every 6-12 months) to screen for HCC. Patients who are HBeAg positive should be considered as candidates for anti-viral therapy (see Figure 2) . Traditionally, only patients with high levels of HBV DNA (410 5 copies/ml) and abnormal ALT levels were considered to be treatment candidates, but this threshold has been called into question recently. It is known that HBV DNA levels o10 5 copies/ml can be associated with significant intrahepatic HBV DNA and cccDNA levels. Recently published data suggest that HBV DNA levels 410 4 copies/ml is a risk factor for developing HCC, independent of HBeAg, ALT levels, and the presence of cirrhosis. 39 Additionally, patients who are HBsAg (À) with undetectable HBV DNA by hybridization who have developed HCC and cirrhosis have been found to have HBV DNA when checked by polymerase chain reaction. [40] [41] [42] In summary, the threshold HBV DNA level associated with liver disease is not known and patients with o10
5 copies/ml may still be at risk for progressive liver disease. Recently published treatment guidelines by Keefe et al. 43 have recommended HBV DNA testing by polymerase chain reaction, and for patients with o10
5 copies/ml and normal ALT levels consideration of performing a liver biopsy to assess histology. It should be noted, however, that patients with normal ALT have never been studied adequately in clinical trials. Further data to support a low threshold for biopsy in patients with renal disease arises from studies showing lower transaminases in patients with renal disease despite active inflammation on liver biopsy. 44 Those who are e antigen negative with high levels of DNA should also be considered potential candidates for therapy. (See Figure 3 ) At our center, these patients would be recommended to have a liver biopsy to further stratify their risk for developing chronic liver disease, but some centers would opt to treat without a biopsy if HBV DNA was greater than 10 4 copies/ml. We feel that HBeAg-negative patients pre-renal transplant, with little inflammation on biopsy may benefit from a strategy of observation until closer to kidney transplantation as continuous therapy is required, which would increase the likelihood of development of resistance. Certainly those with lower levels (10 3 -10 4 copies/ ml) of circulating DNA should also be considered for liver biopsy to further evaluate the degree of hepatic inflammation before deciding on treatment for hepatitis B. Patients with p10 3 copies/ml are not candidates for current anti-viral therapy in the absence of immunosuppression. After transplant, all patients should be treated with lamivudine or lamivudine plus adefovir until further data on entecavir in the post-transplant setting is available to prevent viral reactivation and flares.
VACCINATION
Treatment of hepatitis B would be obviated if everyone were vaccinated. Vaccination is currently required for all children in the US. Additionally, vaccination is recommended for all patients with chronic renal disease, patients on HD, health care workers, and sexually active individuals with multiple partners. Vaccines are administered in a series of three shots over 6 months and induce antibodies that will neutralize HBsAg in 495% of people. Success rates of vaccination in HD patients, however, is significantly lower, estimated to be 50-60%, owing to immune system depression related to uremia. 45, 46 It is well established that vaccine success is inversely related to the degree of renal dysfunction such that an 'earlier is better strategy' should be employed in vaccinating patients with renal disease. 47 Many different strategies have been looked at to improve vaccination success in HD patients such as administering the vaccine more often, intra-dermal administration, and coadministration with different agents such as erythropoietin and interluekin-2. 48, 49 Recent data suggest that a reinforced administration schedule of every 2 weeks with intradermal injection of 20 mg of Energix-B s recombinant vaccine results in a 96.9% seroconversion rate after 1 year with a peak HBsAb titer at 3.971.7 months. This approach is also reported to be cost effective. 50 There are also efforts to improve the vaccine itself. A recently published study looked at HB-AS04, a vaccine for hepatitis B that uses an adjuvant system to booster its immunogenicity. The addition of an adjuvant system, AS04, which is composed of aluminum salt and a specific form of lipid A, results in increased production of cytokines, and a more robust immune response. In a study of 165 patients with renal disease (defined as creatinine clearance p30 ml/ min), use of the Hb-AS04 vaccine resulted in 91% response rate (defined as anti-HBsX10 mIU/ml) compared to 84% of those given conventional vaccine (in this case, Engerix TM ). These differences were persistent and were seen at 36 months follow-up with 73% of those who received HB-AS04 maintaining protective anti-HBs compared to 52% of those who received standard vaccine. Additionally, the use of the HB-AS04 vaccine was associated with more rapid development of antibody formation (74% at 3 months vs 52%) when compared to controls, which makes it particularly useful in this high-risk patient population. There was, however, a 41% rate of injection site pain compared to 19% in the standard vaccine group. 51 Thus, with improving vaccines and varied approaches to administering the vaccine, our ability to decrease the HBV transmission rate in patients with renal disease will continue to improve. However, though it is believed that immunity is lifelong, the CDC recommends that HD patients have HBsAb titers checked on a yearly basis such that booster vaccine can be administered if necessary.
SUMMARY
There are no definitive therapeutic guidelines that outline which patients to treat, with which agent, and for how long.
In fact, patients with chronic hepatitis B comprise such a varied group of patients with various degrees of liver disease (and function) that treatment indications and end points are not yet clearly established. It is most likely that combination therapy will replace monotherapy as the mainstay of treatment. What remains to be further elucidated is which drugs will be most efficacious, best tolerated, and associated with the lowest rates of resistance. Additionally, timing of initial therapy and duration of therapy need to be further assessed. The role of HBV genotyping and resistance testing also needs to be further explored. The recent FDA approval of entecavir and the myriad of new products currently being studied attest to the fact that this is a growing problem and new data continue to support the use of therapy in a growing number of patients, particularly those with renal disease, both in the pre-and post-transplant settings.
